DTX 101

Drug Profile

DTX 101

Alternative Names: AAVrh10FIX; DTX101; Wild-type FIX AAVrh10 vector

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Dimension Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia B

Most Recent Events

  • 10 May 2017 Dimension Therapeutics terminates a phase I/II trial in Haemophilia B in USA and Bulgaria as the analysis did not meet the company's minimum target product profile for continued development or future commercialisation (Parenteral) (NCT02618915)
  • 10 May 2017 Discontinued - Phase-I/II for Haemophilia B in USA and Bulgaria (Parenteral)
  • 31 Jan 2017 Preliminary top-line efficacy and adverse events data from a phase I/II trial in Haemophilia B released by Dimension Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top